News

Chimerix has presented updates on the development of the antiviral compound, CMX001, to the World Health Organization (WHO) and the Global Health Security Initiative (GHSI). CMX001 is a

DSM Pharmaceutical has entered into a manufacturing alliance with Galenix where DSM will be the preferred commercial scale manufacturing partner for Galenix commercial products on a global basis.

Under the alliance, Epic and its employees and consultants are and will continue using a portion of the Registrant’s facility located at New Jersey, for the purpose of

Daiichi Sankyo has launched a new Phase III trial of its anti-influenza agent, CS-8958. The company’s goal is to gain an influenza prevention indication in Japan. The trial

FDA has launched Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use. Margaret Hamburg, commissioner of FDA and Janet Woodcock, director

NovaDel Pharma (NovaDel) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for claims under US Patent Application No 10/671,715, entitled; Buccal, Polar

Bristol-Myers Squibb has reported that FDA has approved a labeling update for Reyataz to include long-term data from the Castle study. The Castle study assessed a once-daily Reyataz/ritonavir

Abraxis BioScience’s chemotherapy agent, ABRAXANE for injectable suspension, has received orphan drug designation from the Office of Orphan Products Development of the FDA. It is intended for the

The study was aimed at comparing the bioavailability and pharmacokinetics of cyclosporine after intravenous administration of NeuroSTAT, a Cremophor EL-free lipid emulsion, and Sandimmune Injection in healthy volunteers.